New Drug Approvals Archive - March 2004

Iquix (levofloxacin ophthalmic) Ophthalmic Solution

Date of Approval: March 1, 2004
Company: Santen
Treatment for: Corneal Ulcers

Marketing Status: Discontinued

Iquix (levofloxacin) is a topical fluoroquinolone indicated for the treatment of bacterial corneal ulcers.

• Iquix Santen - Treatment for Bacterial Corneal Ulcers
• Iquix (levofloxacin ophthalmic) FDA Approval History

Sensipar (cinacalcet) Tablets

Date of Approval: March 8, 2004
Company: Amgen Inc.
Treatment for: Secondary Hyperparathyroidism, Hypercalcemia of Malignancy

Sensipar (cinacalcet) is a calcimimetic agent indicated for the treatment of secondary hyperparathyroidism in dialysis patients and for the treatment of hypercalcemia in patients with parathyroid carcinoma.

• Sensipar Amgen Inc. - Treatment for Secondary Hyperparathyroidism in dialysis patients
• Sensipar (cinacalcet) FDA Approval History

Follistim AQ (follitropin beta) Injection

Date of Approval: March 24, 2004
Company: Organon USA Inc.
Treatment for: Female Infertility, Hypogonadism -- Male, Ovulation Induction

Follistim AQ (follitropin beta) is human follicle-stimulating hormone prescribed for women undergoing assisted reproductive treatments (ART) such as in vitro fertilization (IVF), and for the induction of ovulation to achieve pregnancy, and for men with hypogonadism.

• Follistim AQ Organon USA Inc. - Treatment for Infertility
• Follistim AQ (follitropin beta) FDA Approval History